LAZARD ASSET MANAGEMENT LLC - XERIS PHARMACEUTICALS INC ownership

XERIS PHARMACEUTICALS INC's ticker is and the CUSIP is 98422LAA5. A total of 6 filers reported holding XERIS PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.4%.

Quarter-by-quarter ownership
LAZARD ASSET MANAGEMENT LLC ownership history of XERIS PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$11,212
-10.4%
11,500,0000.0%0.02%0.0%
Q2 2023$12,519
+32.6%
11,500,000
+9.5%
0.02%
+25.0%
Q1 2023$9,439
+8.9%
10,500,0000.0%0.01%0.0%
Q4 2022$8,668
-99.9%
10,500,0000.0%0.01%
-14.3%
Q3 2022$9,802,000
+2.9%
10,500,0000.0%0.01%
+7.7%
Q2 2022$9,526,000
-21.4%
10,500,0000.0%0.01%
-7.1%
Q1 2022$12,123,000
-6.8%
10,500,0000.0%0.01%0.0%
Q4 2021$13,013,000
+4.6%
10,500,0000.0%0.01%0.0%
Q3 2021$12,446,000
-20.7%
10,500,000
+5.0%
0.01%
-22.2%
Q2 2021$15,687,000
-12.9%
10,000,000
-5.9%
0.02%
-18.2%
Q1 2021$18,010,000
+30.2%
10,625,000
+34.9%
0.02%
+29.4%
Q4 2020$13,836,000
+78.2%
7,875,000
+96.9%
0.02%
+54.5%
Q3 2020$7,763,000
+124.0%
4,000,000
+14.3%
0.01%
+120.0%
Q2 2020$3,466,0003,500,0000.01%
Other shareholders
XERIS PHARMACEUTICALS INC shareholders Q1 2021
NameSharesValueWeighting ↓
Context Partners Fund, L.P. 3,240,000$6,256,0001.36%
Context Capital Management, LLC 3,240,000$6,256,0001.36%
Sessa Capital IM, L.P. 7,450,000$14,444,0001.18%
683 Capital Management, LLC 7,500,000$14,550,0001.07%
SILVERBACK ASSET MANAGEMENT LLC 2,500,000$4,850,0001.02%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 18,000,000$36,116,0000.88%
CAMDEN ASSET MANAGEMENT L P /CA 14,000,000$27,032,0000.86%
Soros Fund Management 6,986,000$13,597,0000.33%
Hudson Bay Capital Management LP 8,200,000$16,003,0000.24%
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) 2,000,000$3,861,000,0000.10%
View complete list of XERIS PHARMACEUTICALS INC shareholders